Phaseline

Companies › Zhuhai Huahaikang Pharmaceutical Technology

Zhuhai Huahaikang Pharmaceutical Technology: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Genitourinary; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
HHK001
GnRH receptor agonist (leuprorelin acetate)
GNRHRPhase 1EndometriosisMar 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07755956HHK001Phase 1EndometriosisGenitourinaryMar 2027

Targets

GNRHR (1)

Companies with the same targets

LG Chem JW Pharmaceutical Amgen AbbVie Pfizer TerSera Therapeutics Qilu Pharmaceutical Kissei Pharmaceutical Changchun GeneScience Pharmaceutical HanAll BioPharma

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.